Suppression of TGF-β1 in human gliomas by retroviral gene transfection enhances susceptibility to LAK cells

Journal of Neuro-Oncology

Volumn 43, Issue 1, 1999, Pages 27-34

  Yamanaka, Ryuya ^a   Tanaka, Ryuichi ^a   Yoshida, Seiichi ^a   Saitoh, Takafumi ^a   Fujita, Kazuyuki ^a   Naganuma, Hirofumi ^b  

^a NIIGATA UNIVERSITY   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Antisense; Malignant glioma; Retroviral gene transfer; TGF 1

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CONTROLLED STUDY; CYTOTOXICITY; GENE THERAPY; GENETIC TRANSFECTION; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNITY; IMMUNOGENICITY; LIFESPAN; LYMPHOKINE ACTIVATED KILLER CELL; MOUSE; NONHUMAN; NUDE MOUSE; RETROVIRUS; SPLEEN CELL; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CELL DIVISION; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; MOLECULAR CLONING; NUCLEIC ACID PROBE;

ANIMALS; ANTISENSE ELEMENTS (GENETICS); CELL DIVISION; CLONING, MOLECULAR; CYTOTOXICITY, IMMUNOLOGIC; GLIOMA; HUMANS; IMMUNOSUPPRESSION; KILLER CELLS, LYMPHOKINE-ACTIVATED; MICE; MICE, NUDE; RETROVIRIDAE; TRANSDUCTION, GENETIC; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0032588413     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006289901702     Document Type: Article

References (35)

1. Rosenberg SA: Immunotherapy and gene therapy of cancer. Cancer Res 51 (18 Suppl): 5074s-5079s, 1991
2. Sporn MB, Roberts AB, Wakefield LM, Assoian RK: Transforming growth factor-beta: biological function and chemical structure. Science 233(4763): 532-534, 1986
3. Cheifetz S, Weatherbee JA, Tsang ML, Anderson JK, Mole JE, Lucas R, Massague J: The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors. Cell 48(3): 409-415,1987
4. Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, Roberts AB, Sporn MB, Goeddel DV: Human transforming growth factor-beta complementary DNA sequence an expression in normal and transformed cells. Nature 316(6030): 701-705, 1985
5. Derynck R, Lindquist PB, Lee A, Wen D, Tamm J, Graycar JL, Rhee L, Mason AJ, Miller DA, Coffey RJ: A new type of transforming growth factor-beta, TGF-beta 3. EMBO J 7(12): 3737-3743, 1988
6. Kehrl JH, Roberts AB, Wakefield LM, Jakowlew S, Sporn MB, Fauci AS: Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol 137(12): 3855-3860, 1986
7. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS: Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 163(5): 1037-1050, 1986
8. Devajyothi C, Kalvakolanu I, Babcock GT, Vasavada HA, Howe PH, Ransohoff RM: Inhibition of interferon-gamma-induced major histocompatibility complex class II gene transcription by interferon-beta and type beta 1 transforming growth factor in human astrocytoma cells. Definition of cis-element. J Biol Chem 268(25): 18794-18800, 1993
9. Rook AH, Kehrl JH, Wakefield LM, Roberts AB, Sporn MB, Burlington DB, Lane HC, Fauci AS: Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 136(10): 3916-3920, 1986
10. Kuppner MC, Hamou MF, Sawamura Y, Bodmer S, de Tribolet N: Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2. J Neurosurg 71(2): 211-217, 1989
11. Jin B, Scott JL, Vadas MA, Burns GF: TGF beta down-regulates TLiSA1 expression and inhibits the differentiation of precursor lymphocytes into CTL and LAK cells. Immunology 66(4): 570-576, 1989
12. Ranges GE, Figari IS, Espevik T, Palladino MA Jr: Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med 166(4): 991-998, 1987
13. Wrann M, Bodmer S, de Martin R, Siepl C, Hofer-Warbinek R, Frei K, Hofer E, Fontana A: T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta. EMBO J 6: 1633-1636, 1987
14. de Martin R, Haendler B, Hofer-Warbinek R, Gaugitsch H, Wrann M, Schlusener H, Seifert JM, Bodmer S, Fontana A, Hofer E: Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family. EMBO J 6(12): 3673-3677, 1987
15. Kuppner MC, Hamou MF, Bodmer S, Fontana A, de Tribolet N: The glioblastoma-derived T-cell suppressor factor/transforming growth factor beta 2 inhibits the generation of lymphokine-activated killer (LAK) cells. Int J Cancer 42(4): 562-567, 1988
16. Bodmer S, Strommer K, Frei K, Siepl C, de Tribolet N, Heid I, Fontana A: Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol 143(10): 3222-3229, 1989
17. Torre-Amione G, Beauchamp RD, Koeppen H, Park BH, Schreiber H, Moses HL, Rowley DA: A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 87(4): 1486-1490, 1990
18. Schluesener HJ: Transforming growth factors type beta 1 and beta 2 suppress rat astrocyte autoantigen presentation and antagonize hyperinduction of class II major histocompatibility complex antigen expression by interferon-gamma and tumor necrosis factor-alpha. J Neuroimmunol 27(1): 41-47, 1990
19. Jachimczak P, Bogdahn U, Schneider J, Behl C, Meixensberger J, Apfel R, Dorries R, Schlingensiepen KH, Brysch W: The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J Neurosurg 78(6): 944-951, 1993
20. Tada T, Yabu K, Kobayashi S: Detection of active form of transforming growth factor-beta in cerebrospinal fluid of patients with glioma. Jpn J Cancer Res 84(5): 544-548, 1993
21. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE: Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 93(7): 2909-2914, 1996
22. Naganuma H, Sasaki A, Satoh E, Sakihama T, Tasaka K, Nukui H: Improved bioassay for the detection of transforming growth factor-beta 1 and beta 2 in malignant gliomas. Neurol Med Chir 34(3): 143-149, 1994
23. Mann R, Mulligan RC, Baltimore D: Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 33(1): 153-159, 1983
24. Yamanaka R, Tanaka R, Yoshida S, Saitoh T, Fujita K: Growth inhibition of human glioma cells modulated by retrovirus gene transfection with antisense IL-8. J Neurooncol 25(1): 59-65, 1995
25. Nishiyama A, Onda K, Washiyama K, Kumanishi T, Kuwano R, Sakimura K, Takahashi Y: Differential expression of glial fibrillary acidic protein in human glioma cell lines. Acta Neuropathol 78(1): 9-15, 1989
26. Yamanaka R, Tanaka R, Yoshida S, Mori H, Takeda N, Satoh M: Effects of ACNU and cranial irradiation on the mouse immune system. Neurol Med Chir 33(2): 65-70, 1993
27. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratories, Cold Spring Harbor, New York, 1989, pp 7.2-7.87
28. Bogdahn U, Fleischer B, Rupniak HTR: T-cell mediated cytotoxicity in human glioma. In: Walker MD, Thomas DGT(eds) Biology of Brain Tumour. Martinus Nijhoff, Boston, 1986, pp 501-507
29. Weizsaecker M, Deen DF, Rosenblum ML, Hoshino T, Gutin PH, Barker M: The 9L rat brain tumor: description and application of an animal model. J Neurol 224(3): 183-192, 1981
30. Sampson JH, Ashley DM, Archer GE, Fuchs HE, Dranoff G, Hale LP, Bigner DD: Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. Neurosurg 41(6): 1365-1372, 1997
31. Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E, Long Z, Chiang Y, McGarrity GJ, Muul LM, Katz D, Blaese RM, Oldfield EH: Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nature Med 3(12): 1354-1361, 1997
32. Onodera M, Nelson DM, Yachie A, Jagadeesh GJ, Bunnell BA, Morgan RA, Blaese RM: Development of improved adenosine deaminase (ADA) retroviral vectors. J Virol 72(3): 1769-1774, 1998
33. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med 1(9): 938-943, 1996
34. Feng M, Jackson WH, Goldman CK, Rancourt C, Wang M, Dusing SK, Siegal G, Curiel DT: Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nature Biotech 15: 866-870, 1997
35. Wahlfors JJ, Xanthopoulos KG, Morgan RA: Semliki forest virus-mediated production of retroviral vector RNA in retroviral packaging cells. Hum Gene Ther 8: 1997